SBTi Approves Piramal Pharma’s GHG Reduction Targets
Monday, 16 September 2024, 17:32
The Significance of SBTi Approval
The Science Based Targets initiative (SBTi) has validated and approved India's Piramal Pharma’s near-term greenhouse gas (GHG) reduction targets. This landmark decision emphasizes the company’s commitment to environmental sustainability and proactive measures addressing climate change.
Key Components of Piramal Pharma’s Strategy
- Clear GHG Reduction Goals:
- Alignment with Global Standards:
- Engagement with Stakeholders:
The approval from SBTi reinforces Piramal Pharma's ongoing commitment to reducing our ecological footprint, setting a precedent for others in the pharmaceutical sector.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.